Status:
COMPLETED
Observational Study With InnoLet® in Daily Clinical Practice
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diabetes mellitus (Type 1 or type 2)
- Need insulin treatment
Exclusion
Key Trial Info
Start Date :
March 23 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2005
Estimated Enrollment :
1030 Patients enrolled
Trial Details
Trial ID
NCT01492959
Start Date
March 23 2004
End Date
March 23 2005
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Seoul, South Korea, 137-920